Glucagon-Like Peptide-1 Receptor Agonists and Acute Pancreatitis: Current Evidence and Clinical Implications
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated remarkable efficacy in the management of diabetes and obesity; however, their potential association with acute pancreatitis has been debated since their early clinical use. Numerous cases of suspected GLP-1 RA-related pancreatitis have been reported in the literature and pharmacovigilance databases, raising concerns about their safety. This review aims to examine the clinical and mechanistic evidence linking GLP-1 RA use to acute pancreatitis, including recent clinical studies, meta-analyses, and pathophysiological investigations. Based on the latest clinical evidence and practice guidelines, we propose strategies for the safe and appropriate use of GLP-1 RAs in clinical practice.
Fields of Study & Subjects
Diabetes Treatment and Management
Pancreatitis Pathology and Treatment
Pharmacovigilance and Adverse Drug Reactions
Publication details
- Journal / source
- The Korean Journal of Pancreas and Biliary Tract
- Volume
- 31
- Issue
- 1
- Pages
- 1–7
- Publication date
- 30 January 2026
- Language
- EN